lidocaine and adrenalin
PreclinicalSmall molecule
lidocaine and adrenalin is one of 16 small molecule programs targeting Cardiac Arrhythmia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Cardiac Arrhythmia
#DrugCompanyPhaseTrials
1Klor-Con
NovartisApproved
Colcrys
Jazz PharmaceuticalsApproved
Tambocor
AAlvogen Korea
Approved
Cordarone
WWyeth-Lederle Vaccines
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Multaq
SanofiApproved
Mexitil
Boehringer IngelheimApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lidocaine and adrenalin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUri farkash